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On the lupus-prone MRL-lpr/lpr (MRL-lpr) back-
ground, AM14 rheumatoid factor (RF) B cells are
activated, differentiate into plasmablasts, and un-
dergo somatic hypermutation outside of follicles.
Using multiple strategies to impair T cells, we found
that such AM14 B cell activation did not require
T cells but could be modulated by them. In vitro,
the signaling adaptor MyD88 is required for IgG
anti-chromatin to stimulate AM14 B cell proliferation
when T cells are absent. However, the roles of Toll-
like receptors (TLRs) in AM14 B cell activation
in vivo have not been investigated. We found that ac-
tivation, expansion, and differentiation of AM14 B
cells depended on MyD88; however, mice lacking
either TLR7 or TLR9 displayed partial defects, indi-
cating complex roles for these receptors. T cell-inde-
pendent activation of certain autoreactive B cells,
which gain stimuli via endogenous TLR ligands
instead of T cells, may be the initial step in the gener-
ation of canonical autoantibodies.
INTRODUCTION
Systemic autoimmune diseases such as Systemic Lupus Eryth-
ematosus (SLE) and Rheumatoid Arthritis (RA) are characterized
by the production of canonical diagnostic autoantibodies, such
as anti-nuclear antibodies and rheumatoid factors (RFs) (Tan,
1989). It has become increasingly clear that B cells play impor-
tant pathogenic roles beyond autoantibody secretion. The signif-
icance and importance of the multiple roles of B cells—in partic-
ular, their ability to interact with T cells—has recently been
dramatically emphasized by the responsiveness of human and
murine systemic and organ-specific autoimmune diseases to
therapeutic B cell depletion. T cell-mediated pathology was
modulated in these individuals, and clinical remissions often oc-
curred prior to and not in correlation with reductions in autoanti-
body levels (Browning, 2006).
The importance of T cell-B cell interaction has been demon-
strated in lupus-prone MRL-lpr animals lacking CD4+ or ab
T cells, because these animals have delayed, less-severe dis-
ease and reduced autoantibody titers (Connolly et al., 1992;
Peng, 1998; Peng et al., 1996b). Conversely, the addition of au-toreactive T cells to preautoimmune or nonautoimmune mice
has led to autoreactive B cell activation and autoantibody secre-
tion (Adams et al., 1991; Ando et al., 1987; Fields et al., 2005b)
and even loss of anergic features (Seo et al., 2002). Although
the nature of these B cell-T cell interactions is still not clarified,
it is reasonable to think that the same types of B cells that gen-
erate cardinal autoantibodies are also providing activation
signals to T cells that recognize cognate autoantigens. For
example, a dsDNA-specific B cell might be stimulated by
chromatin, take it up, and present histone peptides to histone-
peptide-specific CD4+ T cells, resulting in proliferation and differ-
entiation of the T cells, as well as in delivery of T cell help signals
to the B cell.
Indeed, autoantibodies reflect the hallmarks of T cell-depen-
dent responses—they are often isotype switched, somatically
mutated, clonally expanded, and affinity matured. Hence, ger-
minal centers (GCs) were presumed to be the source of these
autoantibodies. However, recent data from our lab, coupled
with data from several other studies, have questioned whether
GCs are obligatory sites of affinity-based selection and muta-
tion of autoreactive B cells. Using mice with an Ig-Tg that in-
creases the frequency of B cells that recognize self-IgG2a
(the rheumatoid factor, or ‘‘RF,’’ specificity), we found that
spontaneous, autoantigen-specific responses in the spleen
were largely taking place extrafollicularly, at the T cell zone-
red pulp border. At this location, actively dividing B cells and
plasmablasts were observed, and microdissection experi-
ments demonstrated that somatic hypermutation (SHM) was
taking place in situ (William et al., 2002). Anti-DNA responses
have also been observed to take place at a similar site (Jacob-
son et al., 1995). It is notable that T cell-independent re-
sponses to foreign Ags also occur at this site. The roles of
T cells in activating autoreactive B cells in the extrafollicular re-
action have been little explored (Fields et al., 2005a; Fields
et al., 2005b).
In addition to the potential effects of T cells on the autoanti-
body response, a second important signal, transduced via Toll-
like receptors (TLRs) that recognize endogenous Ags, has been
recognized. This was first observed with the use of the AM14
Tg mouse system. It was demonstrated that IgGs that recog-
nized chromatin and presumably formed immunological com-
plexes (ICs) with it were highly mitogenic for AM14 B cells
in vitro, whereas control ICs were not; moreover, this mitogenic
activity was dependent upon MyD88 and eventually pinned, to
a large extent, to TLR9 (Leadbetter et al., 2002; Viglianti et al.,
2003). The in vivo relevance of this signal for autoreactive B cell
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T Cell-Independent TLR-Dependent RF B Cell ActivationFigure 1. Spontaneous Activation of AM14 B Cells Is T Cell Dependent
(A) Serum levels of AM14 protein were measured by ELISA analysis of samples collected every 2 weeks from Tg WT (n = 5, gray diamonds) and Tg Tcrb/ mice
(n = 6, black squares).
(B) AM14 (4-44+) AFCs as detected by ELISpot. Error bars represent 1 SEM (p = 0.0022).
(C and D) Immunofluorescent staining shows red-pulp macrophages (green), CD4+ T cells (blue), and AM14 (4-44+) B cells (red) in splenic sections of 18-week-old
mice. Original magnification 2003. Note the lack of AM14 B cells in the T cell-deficient mice (D).activation was supported by the phenotype of MyD88-, TLR7-
and TLR9-deficient autoimmune-prone mice (Christensen et al.,
2005; Christensen et al., 2006; Lau et al., 2005; Sadanaga
et al., 2007). Anti-nuclear Abs and RFs were absent in
MyD88-deficient mice, whereas anti-chromatin was lost in
TLR9-deficient mice and anti-RNA was missing in TLR7-defi-
cient animals. Interestingly, however, concentrations of serum
RF were not reduced in either TLR7- or TLR9-deficient lupus-
prone MRL-lpr mice (unpublished observations). Because TLR
signaling can occur in many cell types and at many stages of
activation, exactly how TLRs control autoreactive B cell activa-
tion and autoantibody production in vivo remains to be fully
elucidated.
Here, we have used the AM14 Tg system, along with a newly
described method for inducing the extrafollicular RF B cell reac-
tion in vivo by administration of IgG anti-chromatin (Herlands
et al., 2007), in order to study the roles of both T cells and
TLRs in the activation of autoreactive B cells. Administration of
anti-chromatin to induce the extrafollicular AM14 response
allowed us to visualize its initiation and, thereby, to disentangle
primary and secondary effects. We have used a combination
of inhibition and genetic approaches in the context of both spon-
taneous and induced RF responses. These studies have pro-
vided surprising insights into how autoreactive extrafollicular B
cell responses are initiated and controlled.
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Spontaneous Activation of AM14 B Cells Is T Cell
Dependent
AM14 H chain Tg MRL-lpr mice (Tg WT mice) spontaneously un-
dergo an abrupt expansion of RF-secreting B cells which can be
identified with the anti-idiotype antibody 4-44. This process of
‘‘conversion’’ to autoimmunity occurs between 10 and 20 weeks
of age (William et al., 2005a). To determine whether T cells were
required for conversion, we backcrossed the AM14 H transgene
to ab T cell-deficient MRL-lpr Tcrb/ mice (Tg Tcrb/). We be-
gan tracking the concentration of AM14 Ab in the serum of Tg WT
and Tg Tcrb/ mice when the mice were 8 weeks of age. There
was no detectable serum AM14 Ab in Tg Tcrb/ mice at any
time, whereas we saw increasing amounts in the Tg WT mice
as they aged (Figure 1A). To ensure that this was not a delayed
response in the T cell-deficient animals, we extended the track-
ing to 30 weeks, well beyond the time by which most T cell-suf-
ficient animals have elevated serum AM14 Ab, yet none of the Tg
Tcrb/ animals developed detectable amounts of serum AM14.
In addition, there were few AM14 antibody-forming cells (AFCs)
in spleens of 30-week-old Tg Tcrb/ mice, in contrast to their
high numbers in Tg WT mice (Figure 1B). We also identified
splenic AM14 idiotype-expressing (4-44+) cells in situ by immu-
nofluorescent staining. The morphology of these brightly stained
Immunity
T Cell-Independent TLR-Dependent RF B Cell Activationcells with ample cytoplasm suggests that they are AFCs. There
was a complete absence of AM14 AFCs in the spleens of
30-week-old Tg Tcrb/ mice, though they were clearly seen in
Tg WT animals at the T cell zone-red pulp border (Figures 1C
and 1D; note also the absence of most CD4+ T cells, with remain-
ing cells being DCs).
Anti-Chromatin Driven Activation of AM14 B Cells Is ab
and gd T Cell Independent
AM14 B cells are specific for IgG2a, a class-switched immuno-
globulin. Because T cell-deficient MRL-lpr mice have markedly
reduced concentrations of IgG2a autoantibodies (Peng et al.,
1996b), we wondered whether the absence of AM14 B cell acti-
vation in Tg Tcrb/ mice was due to a lack of Ag for BCR stim-
Figure 2. Anti-Chromatin Drives AM14 B
Cell Activation in a T Cell-Independent
Manner
(A) Representative FACS plots of live cells from
PL2-3- and PL2-8-treated Tg Wt (‘‘WT’’) and Tg
Tcrb/ mice. Gates identify AM14 B cells
(4-44+, CD22lo) and plasmablasts (4-44+,
CD22hi). Note the induction of plasmablasts in
both types of mice by PL2-3 but not PL2-8.
(B) AM14 (4-44+) AFCs determined by ELISpot
analysis of Tg WT and Tg Tcrb/ mice treated
with PL2-3 hybridoma (n = 33 and 30, respectively)
or PL2-8 hybridoma (n = 9 and 6, respectively) or
immunized with IgG2a anti-NP/NP-CGG ICs in
alum (n = 3 and 3, respectively). For Tg WT and
Tg Tcrb/ mice, treatment with PL2-3 was statis-
tically different as compared to that with PL2-8 or
protein IC (p < 0.0001). The values for Tg WT and
Tg Tcrb/ mice treated with PL2-3 were not sta-
tistically different.
(C and D) Micrographs of immunofluorescent
staining of splenic sections from Tg WT and Tg
Tcrb/ mice showing red-pulp macrophages
(green), CD4+ T cells (blue), and AM14 (4-44+) B
cells (red).
(E) Histograms showing PNA binding on live,
4-44+, CD22hi cells from Tg WT and Tg Tcrb/
mice immunized with IgG2a anti-NP/NP-CGG
ICs in alum.
(F and G) Micrographs of immunofluorescent
staining showing AM14 (4-44+) B cells (red), red-
pulp macrophages (blue) and PNA+ GC cells
(green) in splenic sections of mice described in
(E). In (F) note the large 4-44+ GC, as recognized
by the yellow color of the light zone.
ulation (i.e., IgG2a or IgG2a-containing
ICs) rather than a lack of a T cell-B cell in-
teraction required for direct RF B cell
stimulation. Recently, we have described
the ability of the IgG2a anti-chromatin
PL2-3 (via intraperitoneal [i.p.] injection
of PL2-3 hybridoma cells or purified
protein) to activate AM14 B cells to prolif-
erate, differentiate, and hypermutate at
extrafollicular sites in the spleen (Her-
lands et al., 2007). Neither IgG2b anti-
chromatin nor IgG2a anti-hapten or self-reactive Ab that does
not bind chromatin had this property (Herlands et al., 2007).
We used this system to bypass the potential role of T cells in gen-
erating the isotype-switched BCR ligand for AM14 by providing it
exogenously. PL2-3 or control PL2-8 (IgG2b anti-chromatin)
hybridomas were injected into Tg WT and Tg Tcrb/ MRL-lpr
animals. Surprisingly, T cell-deficient animals receiving PL2-3
developed AM14 CD22lo plasmablasts at frequencies compara-
ble to those of T cell-sufficient mice (Figure 2A and data not
shown). Furthermore, there were indistinguishable numbers of
AM14 AFCs in the spleens of both T cell-deficient and T cell-suf-
ficient animals (Figure 2B). The localization of activated cells in
the spleen was also similar in the two strains. Immunofluores-
cence analysis showed clustering of AM14 B cells at the T cell
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T Cell-Independent TLR-Dependent RF B Cell Activationzone-red pulp border, outside of B cell follicles in Tg WT
(Figure 2C) and Tg Tcrb/ mice (Figure 2D) that received PL2-
3 but not PL2-8 (data not shown).
As a further control, to ensure that the Tg Tcrb/ mice were
indeed unable to respond to T cell-dependent antigens, we
tested the ability of foreign protein-containing ICs to elicit an
AM14 GC response. We previously reported that IgG2a anti-
TNP and TNP-KLH ICs as well as IgG2a anti-NP and NP-CGG
ICs can stimulate an RF GC response in Tg WT animals (Herlands
et al., 2007; William et al., 2002; William et al., 2006). Immuniza-
tion with IgG2a anti-NP+NP-CGG ICs generated AM14 PNA+ GC
cells detected by both FACS (Figure 2E) and immunofluores-
cence (Figure 2F) in Tg WT mice. However, Tg Tcrb/ mice pro-
duced neither AM14 PNA+ cells (Figure 2E) nor AM14+ GCs
(Figure 2G). Consistent with previous observations (William
et al., 2002; William et al., 2006), this immunization with protein
ICs produced an exclusively GC response, and it did not gener-
ate AM14 AFCs in either Tg Tcrb/ or Tg WT mice (Figures 2B,
2F, and 2G). Together, these data demonstrate that Tg Tcrb/
mice are incapable of generating T cell-dependent responses
but are fully able to support the extrafollicular AM14 B cell
response elicited by IgG2a anti-chromatin.
Tg Tcrb/ mice have increased numbers of gd T cells, which
could potentially provide help for AM14 B cells in the absence of
ab T cells (Peng et al., 1996a). For exclusion of this possibility,
a gd-depleting antibody, UC7 (Houlden, 1989), was used to elim-
inate the gd T cells during PL2-3 treatment (Hiromatsu, 1992).
Figure 3A shows successful depletion of gd T cells to less than
1% of live cells in mice treated with UC7, but not in those treated
with rat IgG. Despite effective gd cell depletion, there was no
effect on splenic AM14 ELISpots in PL2-3 treated animals
(Figure 3B). Thus, activation of AM14 B cells by PL2-3 anti-chro-
matin is both ab and gd T cell independent, suggesting that the
lack of spontaneous activation in Tg Tcrb/ MRL-lpr mice
was due to the lack of IgG2a autoantigen rather than the absence
of T cell help.
CD4 T Cells Potentiate but Are Not Required
for Sustained Activation of AM14 B Cells
Though mice lacking ab and gd T cells clearly generated a robust
RF response within 1 week of exposure to IgG2a anti-chromatin,
it remained possible that T cells could promote or facilitate the
activation of AM14 B cells in the spontaneous RF response. To
address this issue, we treated autoimmune AM14 mice with
the CD4 monoclonal antibody GK1.5. Consistent with previous
reports (Wofsy and Seaman, 1987), we achieved partial deple-
tion (40%–70%) of circulating CD4+ T cells in lupus-prone
mice, in contrast to 90%–99% depletion in BALB/c mice (Figures
S1A–S1D, available online). The remaining CD4+ cells were
apparently rendered functionally inactive, as evidenced by their
complete opsonization with GK1.5 in vivo, by their marked sur-
face CD4 downregulation, and, most importantly, by the inability
of GK1.5-treated mice to mount a T cell-dependent humoral re-
sponse (Figures S1E–S1G). This ability of GK1.5 to inhibit T cell
function in the absence of complete depletion has been previ-
ously documented in autoimmune mice (Carteron et al., 1989).
We then used GK1.5 to functionally impair CD4+ T cell help for
2–4 weeks immediately after spontaneous conversion in AM14
Tg mice. In Tg WT mice treated with GK1.5 for 2 weeks, in the fre-
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that received control antibody (p = 0.04, Figure 4A). Thus, T cells
do contribute to an ongoing spontaneous RF response. Because
the AM14 plasmablast response is rapidly turning over (William
et al., 2005b), we extended the treatment duration to determine
whether this enhanced the effect. However, in mice treated for 4
weeks, there was still the same reduction by half of the frequency
of AM14 AFCs (p = 0.0052 compared to control, Figure 4A). De-
spite 4 weeks of GK1.5 treatment, the number of splenic AM14
AFCs was more than 5-fold greater than in age-matched, noncon-
verted Tg WT mice (p = 0.0006, Figure 4A). Thus, the ability of
AM14 B cells to differentiate into AFCs was not completely abro-
gated, and a significant autoantibody response was maintained
in the absence of functional CD4+ T cell help.
Conversion was previously shown to include activation of
CD22hi B cells, as well as development of CD22lo plasmablasts
(William et al., 2005b). As predicted by the ELISpot analysis,
GK1.5-treated mice had reduced frequencies of AM14 CD22lo
cells as compared to control mice (p = 0.0081 for 2 wk treatment,
p = 0.0052 for 4 wk treatment), although a residual population of
phenotypic plasmablasts persisted in the absence of T cell help
(Figures 4B and 4C). We then examined activation-marker
expression and proliferation of AM14 B cells and plasmablasts
Figure 3. Anti-Chromatin Activation of AM14 B Cells Is ab and gd
T Cell Independent
(A) Representative FACS plots of live cells from spleens of Tg WT and Tg
Tcrb/ mice injected with either gd-depleting antibody UC-7 or control rat
Ig during PL2-3 hybridoma treatment. Gates identify ab and gd T cell popula-
tions.
(B) AM14 (4-44+) AFCs determined by ELISpot. Mice were injected with either
control rat Ig (black bars) or UC-7 (gray bars) during PL2-3 hybridoma treat-
ment (n = 4 and 4, respectively, for each of WT and Tcrb/). Mice that received
neither PL2-3 nor antibody treatment were included as negative controls (n = 4
for each of WT and Tcrb/, white bars). Asterisks indicate a p value < 0.05.
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T Cell-Independent TLR-Dependent RF B Cell Activationafter GK1.5 treatment. Expression of CD44 and CD69 was de-
creased in CD22hi B cells (p = 0.0164 and 0.0033, respectively),
but a high level of CD44 expression was maintained and CD69
was partially but significantly reduced (p = 0.0115) in CD22lo
plasmablasts (Figure 4D). For assessment of the effect of
GK1.5 treatment on proliferation, the incorporation of 5-bromo-
20-deoxyuridine (BrdU) was measured after a 12 hr labeling
period in mice that had been treated with GK1.5 or control anti-
Figure 4. Reduced but Persistent AM14 Activation in Mice Treated
with Anti-CD4
(A) ELISpot analysis was used to quantify splenic AM14 (4-44+) AFCs in Tg WT
mice treated with control Ig for 2 weeks (black triangles, n = 9) or 4 weeks
(black circles, n = 9), or GK1.5 for 2 weeks (white triangles, n = 9) or 4 weeks
(white circles, n = 7). Age-matched nonconverted Tg WT mice are shown in
black triangles (n = 7).
(B) Identification by FACS of splenic AM14 B cells (4-44+, CD22hi) and plasma-
blasts (4-44+, CD22lo) in control and GK1.5-treated mice.
(C) Percentage of 4-44+ CD22lo plasmablasts in control (black diamonds, n = 9)
and GK1.5-treated (white diamonds, n = 7) mice.
(D) Percentage of CD22hi and CD22lo 4-44+ cells expressing elevated amounts
of CD44 and CD69 in mice treated with control Ig (black bars, n = 9) or GK1.5
(white bars, n = 7).
(E) BrdU incorporation in CD22hi and CD22lo 4-44+ cells from mice treated with
control Ig (black bars, n = 9) or GK1.5 (white bars, n = 7) and given a single dose
of BrdU 12 hr earlier. For C-E, results after 4 weeks of GK1.5 treatment are
shown; similar results were seen after 2 weeks of treatment.
An asterisk indicates a p value < 0.05; double asterisks indicate a p value <
0.01 (Mann-Whitney U test).body. Proliferation was decreased in CD22hi B cells (p = 0.0164)
but was not significantly reduced (p = ns) in CD22lo plasmablasts
after 4 weeks of GK1.5 treatment (Figure 4E). Taken together,
these results suggest that although CD4+ T cells may enhance
spontaneous AM14 B cell activation, a substantial degree of B
cell activation and antibody formation can be maintained in the
absence of T cell help.
Chromatin AntibodiesDrive TCell-Independent Somatic
Hypermutation at Extrafollicular Sites
SHM is classically associated with T cell-dependent GC re-
sponses, but we recently found that SHM occurs robustly in
AM14 B cells at extrafollicular sites of the spleen in Tg WT mice
(Herlands et al., 2007; Kleinstein et al., 2003; William et al.,
2002). The discovery that the extrafollicular AM14 response could
initiate in the absence of T cells raised the important question of
whether SHM occurred in the absence of T cells. For an examina-
tion of this question, small clusters of 4-44+ B cells from splenic
sections of PL2-3 treated Tg MRL-lpr or Tg Tcrb/ MRL-lpr
mice were microdissected (Figure 5A). The endogenous Vk8 L
chains were amplified, cloned, and sequenced (William et al.,
2002). Remarkably, mutations were occurring in Tg Tcrb/
mice (Table 1), as well as in Tg WT mice [data shown in (Herlands
et al., 2007)]. As previously reported, all six picks from Tg WT mice
showed mutation, with an average of 1.8 mutations per sequence
(Herlands et al., 2007). Similarly, all seven picks from Tg Tcrb/
mice had mutation, with 0.94 mutations per sequence (Table 1).
We previously calculated a PCR error rate using Pfu Turbo of <
0.1 mutations per sequence (William et al., 2002); these current
sequences were generated with Pfu Ultra, which has one-third
the error rate (Stratagene). Thus, the observed mutation rates
are far above PCR error. To account for the possibility of generat-
ing multiple copies of a single sequence that do not represent dif-
ferent cells, we also calculated the number of mutations per
unique sequence (Table 1). We found 2.8 and 1.11 mutations
per unique sequence for picks from Tg WT (Herlands et al.,
2007) and Tg Tcrb/ mice, respectively (p < 0.005, Student’s t
test with equal variance). Thus, although T cells are clearly not
required for mutation to occur, T cells promote the accumulation
of mutations, either by increasing the inherent mutation rate or by
promoting longer survival of mutating cells.
Using sequences recovered from each microdissection, we
created genetic-lineage trees that reflect the inferred clonal evo-
lution; representative trees are shown in Figure 5B (William et al.,
2002). Five out of six trees from Tg WT mice (Herlands et al., 2007)
had at least one branch, whereas eight out of nine trees from Tg
Tcrb/mice had at least one branch. On average, each pick from
Tg WT mice had 1.33 branches and each pick from Tg Tcrb/
mice had 1.65 branches. Branching patterns, though not ex-
pected to be extensive after only 7 or fewer days of mutation,
are nonetheless indicative of authentic mutation and clonal ex-
pansion. Both the branching and the number of mutations per
sequence confirm that mutation was occurring at a high rate at
extrafollicular sites in both types of mice treated with PL2-3.
Stimulation of AM14 BCells by Anti-Chromatin Depends
on MyD88 and the Combination of TLR7 and TLR9
Although PL2-3 causes AM14 B cells to proliferate in vitro in
a MyD88-dependent fashion (Leadbetter et al., 2002), the roles
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been well-defined in vivo. Considering that T cell signals are dis-
pensable, we hypothesized that BCR and TLR dual engagement
was required to drive AM14 B cell activation and differentiation in
PL2-3 treated mice. For testing of this hypothesis, PL2-3 and
PL2-8 hybridomas were injected i.p. into Tg WT, Tg Tlr9/, Tg
Tlr7/, Tg Tlr7/ Tlr9/, and Tg Myd88/ mice (all on the
MRL-lpr background).
PL2-3-treated Tg Myd88/ mice had numbers of AM14 AFCs
that were indistinguishable from those of Tg WT mice treated
Figure 5. Somatic Hypermutation Occurs
at Extrafollicular Sites of Tg WT and Tg
Tcrb/ Mice Given IgG2a Anti-Chromatin
(A) Immunohistochemistry showing AM14 B cells
stained with 4-44 anti-idiotype antibody (blue) in
a splenic section from a Tg Tcrb/ mouse treated
with PL2-3 protein every other day for 2 weeks.
Images are from before and after laser microdis-
section. Typical picks contained 10-30 4-44+ B
cells.
(B) Representative genealogical trees from two Tg
WT mice (tree A2 and B3) and two Tg Tcrb/ mice
(trees K1 and L2) treated with PL2-3 protein as
described in (A). The trees demonstrate ongoing
mutation. Circles at the base of trees represent
germline sequences, and non-mutated sequences
found in a pick are listed in this circle. Every other
open circle, or ‘‘node,’’ represents one or more
clones with the same sequence. Tree ‘‘branches’’
are the lines between nodes. The positions of nu-
cleotide mutations are listed alongside branches.
Table 1. Summary of Microdissections and Mutations in T Cell-Deficient MRL/lpr Mice Treated with PL2-3 Hybridoma
Mouse Pick
Tree
Name
Total
Sequences
Total
Mutations
Mutations/
Sequence
Total Unique
Sequences
Total Mutations among
Unique Sequences
Mutations/Unique
Sequence
Trunk
Mutations
11-8-05 G 1 I1 12 11 0.92 2 1 0.50 1
11-8-05 G 2 I2 12 5 0.42 3 3 1.00 1
11-8-05 H 1 J1 12 14 1.6 2 4 2.00 1
11-8-05 H 2 J2 10 2 0.20 3 2 0.67 0
11-8-05 E 1 K1 10 6 0.60 3 3 1.00 1
11-8-05 E 3 K2 11 32 2.91 2 5 2.50 0
10-18-06 E 2 L2 14 6 0.43 3 2 0.67 0
Total 81 76 0.94 18 20 1.11 4
Sequences recovered from 4 Tg Tcrb/ MRL/lpr mice treated with PL2-3 were grouped by pick and assigned to a lettered genealogical tree. Identical
sequences in a pick were conservatively treated as one clone, instead of as the products of multiple cells, and were assigned to one ‘‘unique
sequence.’’
with control PL2-8 and were significantly
lower than those of PL2-3-treated Tg
WT mice (Figure 6A). Interestingly, the
generation of RF AFCs was only partially
TLR9- or TLR7-dependent, because
AM14 AFC numbers, though reduced sig-
nificantly in each knockout strain, were
not completely eliminated. To determine
whether there was redundancy between
TLR7 and TLR9 in provision of essential
signals, we treated AM14 Tg Tlr7 Tlr9 double-mutant mice with
PL2-3. AM14 AFCs were almost absent in these mice after
PL2-3 treatment (Figure 6A), indicating that either TLR7 or
TLR9 can contribute to the response to PL2-3. This was some-
what unexpected, considering that PL2-3 is thought to be an
anti-chromatin DNA (Losman et al., 1992) and only TLR9, not
TLR7, is thought to recognize DNA.
As expected, Tg Myd88/ and Tg Tlr7/ Tlr9/ mice had
lower frequencies of 4-44+ CD22lo cells than did Tg WT mice
(Figures 6B and 6C). Surprisingly, Tg Tlr9/ mice had increased
254 Immunity 29, 249–260, August 15, 2008 ª2008 Elsevier Inc.
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(Figures 6B and 6C). Similarly, Tg Tlr7/ mice had frequencies
of 4-44+ CD22lo cells similar to those of WT mice. This was not
anticipated, given that Tg Tlr9/ and Tg Tlr7/ mice had sub-
stantially fewer AM14 ELISpots than did Tg WT mice and, thus,
reduced numbers of fully fledged AFCs (Figure 6A). Together,
these data suggested that in the absence of either TLR7 or
TLR9, initial activation could proceed normally but complete dif-
ferentiation to a functional AFC was inefficient. To further sub-
stantiate this, we calculated a ratio that reflects efficiency of
complete differentiation: the number of ELISPots (actual AFCs)
divided by the frequency of CD22lo cells identified by FACS (po-
tential AFCs) (Figure 6D). This ratio in TLR-deficient animals was
almost 10-fold lower than that in WT animals, indicating a marked
deficit in completion of AFC differentiation. Consistent with the
flow-cytometry results, AM14 cells were identified by immuno-
fluorescence in both Tg WT and Tg Tlr9/ mice (Figures 6E
and 6F) and in Tg Tlr7/ mice (data not shown). In contrast,
AM14 AFCs were not identified in splenic sections of PL2-3
treated Tg Myd88/ mice (Figure 6G) or PL2-3 treated Tlr7
Tlr9 double-mutant mice (data not shown).
In trying to reconcile these data, we first investigated whether
TLRs have an impact on cell survival. However, we found that
Tlr9/ AM14 cells did not die at a rate different than that of WT
Figure 6. PL2-3-Driven Activation of AM14
B cells Is TLR Dependent
(A) AM14 (4-44+) AFCs detected by ELISpot from
spleens of mice treated for 1 week with PL2-3
hybridoma (black bars, n = 35 for WT, n = 19 for
Tlr9/, n = 10 for Tlr7/, n = 5 for Tlr7/ Tlr9/,
and n = 10 for Myd88/) or PL2-8 hybridoma
(striped bars, n = 10 for WT and n = 5 for Tlr9/).
(B) Representative FACS plots gated on live cells
from Tg WT, Tg Tlr9/, Tg Tlr7/, Tlr7/ Tlr9/
and Tg Myd88/ mice given PL2-3 hybridoma.
(C) Summary of FACS data from multiple experi-
ments showing percent of live cells that are
4-44+ CD22lo. Bars show means.
(D) Ratio of actual ELISPots to plasmablast phe-
notype cells (assessed by FACS as in Figure 6B).
Data derived from Figures 6A and 6C.
(E–G) Micrographs of immunofluorescent staining
showing AM14 (4-44+) B cells (red), red-pulp mac-
rophages (green) and CD4+ T cells (blue). PL2-3
treated Tg WT mouse (E), Tg Tlr9/ mouse (F),
and Tg Myd88/ mouse (G) are displayed. Origi-
nal magnification 1003.
An asterisk indicates a p value < 0.05; double
asterisks indicate a p value < 0.001 (Mann-Whit-
ney U test).
AM14 cells ex vivo, which argues against
death as a cause for the lower ELISpot
counts (data not shown). To examine
whether TLR9 had an effect on prolifera-
tion in AM14 CD22lo cells, we pulsed
mice with BrdU 12 hr before sacrifice.
However, preliminary data (three mice
per group) did not reveal differences in
BrdU incorporation, making this explanation unlikely (data not
shown).
If TLR9 (and TLR7) were important for late-stage differentiation
into AFCs, the large number of AM14 CD22 lo cells could be
indicative of a buildup of preplasmablast cells that cannot fully
differentiate (Culton et al., 2006), thus explaining the excess of
CD22lo cells in the face of reduced numbers of bona fide
AFCs. To address this theory, we assessed expression of differ-
entiation markers on CD22lo AM14 cells from Tg Tlr9/, Tlr7/,
and WT cells. No differences were found in levels of MHCII,
CD38, CD80, or CD86 (data not shown). However, some surface
molecules tested did demonstrate different expression in the
TLR-deficient versus WT strains, including CD43, CD45, and
CD138 (Figure S2).
B Cell-Intrinsic Expression of MyD88 Is Required
for Initial Proliferation of AM14 B Cells
Multiple cell types are capable of MyD88-dependent TLR signal-
ing. To determine whether such signaling was specifically re-
quired in B cells, we performed transfers of MyD88-deficient or
WT B cells into WT recipients, followed by infusion of PL2-3.
Whereas transferred MyD88-intact AM14 H Tg B cells differenti-
ated into AFCs in WT recipient mice, MyD88-deficient B cells
generated no detectable AFCs (Figure 7A). This demonstrates
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Myd88+/ or Myd88/ AM14 Tg B cells were labeled with CFSE and transferred into Balb/c mice that were then treated with anti-chromatin.
(A) 4-44 ELISpot assay of splenocytes. Data compiled from two experiments. Double asterisks indicate a p value < 0.005 (Mann-Whitney U test).
(B) Proliferation of 4-44+ splenocytes. CFSE labeling and flow cytometry was used for the detection of division (Figure S3). Proliferation index was calculated by
dividing the number of 4-44+ B cells that had divided by the number of undivided 4-44+ B cells. Triple asterisks indicate a p value of 0.0001 (unpaired t test).an absolute requirement of MyD88 signaling in B cells for differ-
entiation into AFCs. Given that differentation into AFCs is typi-
cally preceded by proliferation, MyD88 could be required for
proliferation, differentiation, or both. For the examination of this
possibility, AM14 H Tg B cells were labeled with CFSE prior to
transfer and then splenocytes from recipients given PL2-3
were analyzed by FACS. 4-44+ cells from MyD88-deficient
donors proliferated little, if at all, whereas WT 4-44+ cells prolif-
erated and expanded robustly (Figure 7B and Figure S3). Thus,
for the activation of the AM14 extrafollicular response, MyD88
signaling is required within the B cells at the earliest stages of ac-
tivation.
DISCUSSION
It is becoming appreciated that autoreactive B cell responses of-
ten occur extrafollicularly, generating short-lived plasmablasts in
dynamic antiself responses (Weisel et al., 2007). Yet, knowledge
is relatively limited concerning the requirements for initiation and
regulation of this response. Here, we have used the well-charac-
terized AM14 system and our newly developed system for trig-
gering extrafollicular RF responses to begin to dissect this
mode of autoreactive B cell response. We report two important
findings: T cells are not required for initiation of RF responses,
but TLR signals are essential. We also identify overlapping yet
important roles for TLR7 and TLR9, along with qualitative alter-
ations that occur in the absence of either receptor. Finally, we
show a B cell-intrinsic requirement for MyD88 signaling, and
we show that these signals are needed to initiate proliferation.
It has been thought that autoantibody responses in systemic
autoimmunity require T cells (Peng et al., 1996a). Our results sug-
gest that the role of T cells is considerably more complex than
previously believed. Most strikingly, we found that T cells are
dispensable for activation and differentiation of RF B cells to
plasmablasts, provided that the proper antigen is available. Sur-
prisingly, somatic hypermutation at extrafollicular sites also does
not require T cells. On the other hand, we found that T cells do
have a role in ongoing spontaneous responses, given that anti-
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50% reduction in the numbers of plasmablasts. Nonetheless,
the residual RF B cell response was sustained for at least 4
weeks without further decay. It is interesting that although
SHM could take place in the absence of T cells, the number of
mutations per cell was higher in their presence. Whether this is
due to direct effects of T cells in induction of higher amounts of
AID or other required factors or to the sustenance of mutation-
competent cells for more generations is not clear. These definite,
albeit limited, consequences of CD4+ T cell inhibition—coupled
with the fact that CD4+ T cells were not required for a complete
extrafollicular plasmablast response to IgG2a anti-chromatin ad-
ministration—suggests that T cells can amplify a response once
initiated but are not required for the response per se. The notion
that T cells do regulate an ongoing response would reconcile our
data with results from a variety of systems (Peng et al., 1996a;
Peng et al., 1996b; Wofsy, 1993).
A potential caveat to this interpretation is that anti-CD4 treat-
ment did not completely deplete CD4+ T cells. We believe that
CD4+ cells that remained were functionally inhibited, as reported
by others who demonstrated inhibition with nondepleting Abs
(Carteron et al., 1989; Zelenika et al., 2001); residual CD4+
T cells in treated animals were completely opsonized with
GK1.5 in vivo, and, most importantly, these cells had lost the
ability to promote a classic T cell-dependent humoral response.
Until there are methods for the full elimination of CD4+ T cells in
lupus-prone mice in an inducible fashion, we cannot fully ex-
clude that CD4+ T cells are absolutely (rather than relatively) nec-
essary for propagation of an ongoing response.
That T cells do influence the response is consistent with data
indicating that B cells play important roles in activating autoreac-
tive CD4+ T cells, most likely via direct Ag presentation. Our data
suggest that the extrafollicular autoreactive reaction is a relevant
site of B cell-T cell interaction. Previously, we found that some
but not most RF B cells that were engaged in the spontaneous ex-
trafollicular reaction were in contact with T cells (William et al.,
2002; William et al., 2005a). This is consistent with the concept
that extrafollicular plasmablast development is only partially
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be involved in both T cell-independent and T cell-dependent re-
sponses to model antigens and pathogens (MacLennan et al.,
2003). Indeed, an emerging theme is that T cells, if present, can
promote such responses. For example, activated T cells that
can directly collaborate with anti-DNA B cells are critical in stim-
ulating these cells to differentiate at extrafollicular sites (Seo et al.,
2002). Thus, together with data from others, our results suggest
that the extrafollicular activation of autoreactive B cells could
also result in productive B cell-T cell interactions. Presumably,
these interactions in turn lead to T cell activation, though the
direct demonstration of this will likely require in vivo imaging. Ex-
actly how T cells modify the extrafollicular autoreactive B cell re-
sponse is much less clear and will require further investigation
with a combination of inhibitors and genetic manipulation. Cyto-
kines such as IL-4 and IL-21, T cell products that are known to
promote isotype switch as well as B cell proliferation and differen-
tiation (Good et al., 2006), are good candidates. Both CD40L and
ICOS are parts of costimulatory pathways that are important for
GC responses (Tarlinton, 2006), but their role in B cell-T cell inter-
actions elsewhere are little investigated.
In the absence of a requirement for T cell help in the initiation of
RF B cell extrafollicular plasmablast differentiation and SHM, we
found that TLR signals were required. Importantly, the lack of
response in TLR7, TLR9 double-deficient mice identifies these
two as the critical (although potentially redundant) receptors
and excludes other MyD88-dependent receptors. Our in vivo
findings extend previous in vitro data showing that RF B cells
must express MyD88 in order to proliferate in response to
IgG2a anti-chromatin. The transfer studies demonstrated a re-
quirement for MyD88 in B cells in vivo. Thus, although the
need for direct TLR-mediated stimulation of B cells in the
T cell-dependent GC response remains controversial (Gavin
et al., 2006; Meyer-Bahlburg et al., 2007; Pasare and Medzhitov,
2005), it is clearly required for the extrafollicular plasmablast re-
sponse to anti-chromatin ICs, providing support for the notion
that B cells themselves must express relevant TLRs for at least
some types of response (Pasare and Medzhitov, 2005).
Taken together, experiments presented here link the in vitro
response to in vivo differentiation at the site that yields both
anti-DNA and RF responses in autoimmune mice (Jacobson
et al., 1995; Mandik-Nayak et al., 1999; William et al., 2002; Wil-
liam et al., 2005a). The findings establish a physiologic in vivo
context for how TLRs promote activation of certain autoreactive
B cells. Notably, prior in vitro cultures were harvested after two
days and never progressed to differentiation (Leadbetter et al.,
2002), so whether the TLR signal was required for differentiation
to AFC function was unknown. Mechanistic studies revealed
that, in vivo, AM14 cells lacking MyD88 failed to proliferate, indi-
cating that MyD88-mediated signals are required for initial acti-
vation. Of significance, we show that, even in the presence of
T cells, TLR-mediated activation is a nonredundant signal
in vivo. In vitro cultures did not have T cells (or other accessory
cells) (Leadbetter et al., 2002), so it was only shown that TLRs
were required when other potentially important cells were absent
in the culture dish. The lack of clonal expansion, activation, or
differentiation in the absence of MyD88 indicates that therapeu-
tic approaches to TLR inhibition should expect to block the ear-
liest steps of autoreactive B cell activation.It was somewhat surprising that responses were only mod-
estly reduced in the TLR7 or TLR9 single-deficient mice. This
finding could provide insight into the natural chromatin autoanti-
gen in vivo as it is recognized by an authentic disease-associ-
ated autoantibody (e.g., PL2-3). It is possible that PL2-3 directly
binds both DNA and RNA, allowing it to capture ligands for both
TLR7 and TLR9. However, PL2-3 is reported to bind only chro-
matin or nucleosomes (Losman et al., 1993). Similarly, given
the well-documented specificity of TLR7 for RNA and TLR9 for
DNA (Heil et al., 2004; Hemmi et al., 2000; Lund et al., 2004), it
is unlikely that TLR7 directly recognizes the DNA in chromatin.
Rather, we suggest that the partial dependence on TLR7 indi-
cates that the autoAg recognized by PL2-3 in vivo has both
DNA and RNA components. This could be RNA in the process
of transcription or RNA that associates with DNA-binding pro-
teins or becomes associated during the processes of cell death
and release of chromatin.
One unexpected result was that deficiency of TLR7 or TLR9
had a much more profound effect on fully-fledged AFCs than it
did on the proliferating precursors of such cells. This was
reflected in an almost 10-fold alteration in the ratio of these
two cell types. We investigated a number of possible explana-
tions for this result. Certain differentiation markers were consis-
tently altered in the absence of either TLR7 or TLR9, and these
differed between the two TLRs. Though the reason for this is
unclear, this result does indicate that signaling by both TLRs
is required for completion of differentiation, whereas it seems
that signals through either one are sufficient to initiate prolifer-
ation and to permit some, albeit inefficient, differentiation to the
terminal plasmablast. Unexpected dichotomies between TLR7
and TLR9 were also observed in lupus-prone MRL-lpr mice
lacking one or the other TLR, in which TLR7-deficiency
protected against but TLR9-deficiency promoted autoimmune
disease (Christensen et al., 2006). Further work will be required
to discover the details of the differential regulation of both
autoantibody production and disease by these two related
molecules.
Our findings suggest an order in which self-tolerance mecha-
nisms break down, eventually leading to autoimmunity. B cell-T
cell collaboration is currently envisioned as a positive feedback
loop that amplifies autoreactive immune-system activation
(Shlomchik et al., 2001; Weisel et al., 2007). However, there
have been few clues as to whether autoreactive T or B cells
are activated first and where these interactions take place. The
finding that T cell activation is not required for generation of au-
toantibodies supports the proposal that autoreactive B cell acti-
vation is an initial step in systemic autoimmunity, followed by
subsequent activation of autoreactive T cells by B cells. How-
ever, we also find that T cells modify the extrafollicular reaction,
suggesting that subsequent productive B cell-T cell interactions
can occur at this site. This notion links to findings of others that
autoreactive B cells can activate autoreactive T cells in vitro and
in vivo (Lin et al., 1991; Mamula et al., 1994; Singh and Hahn,
1998). Finally, stimulation of TLR7 or TLR9 within RF B cells ap-
pears to be a critical requirement for activation of these cells
whether or not T cell help is available. The central role of the au-
toreactive B cell in this paradigm could help to explain why B cell
depletion is proving so effective in a wide array of autoimmune
diseases (Browning, 2006).
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Mice
The AM14 heavy-chain Tg was backcrossed at least ten generations onto the
MRL-lpr background (William et al., 2002). Tcrb/ MRL-lpr mice (Peng et al.,
1996a) were obtained from Joseph Craft. Tlr9/ MRL-lpr and Tlr7/ MRL-lpr
mice have been described (Christensen et al., 2006). The MyD88 mutant allele
(Kawai et al., 1999) was provided by Shizuo Akira and was backcrossed to
MRL-lpr mice for > 5 generations and then to Tg MRL-lpr mice before being
made homozygous. The MyD88-deficient BALB/c mice were obtained from
Ruslan Medzhitov (Yale) and were backcrossed at least ten times. All mice
were housed under specific pathogen-free conditions. PCR genotyping for
heavy chain was performed as described previously (Shlomchik et al., 1993).
For experiments involving anti-chromatin injection, we used mice 7 weeks
old and younger; it is rare for mice this age to have spontaneous RF B cell ac-
tivation (William et al., 2005a). All experimental procedures were approved by
the Yale Animal Care and Use Committee.
ELISA Analysis
ELISA assays were performed as described (Wang and Shlomchik, 1999). In
brief, plates were coated with 10 mg/ml of anti-IgM (Chemicon) overnight in
PBS, washed, and blocked. Serially diluted samples were incubated in dupli-
cate for 1 hr, followed by washing, detection with anti-idiotype antibody 4-44-
biotin (0.25 mg/ml in 1% BSA/PBS), washing, incubation with streptavidin-al-
kaline phosphatase (Southem Biotechnology), and, finally, development with
p-nitrophenylphosphate. Concentrations were determined with the use of Del-
tasoft software (Biometallics) by comparison to standard curves on each plate.
ELISPOT Analysis
ELISpot analysis was performed as previously described (Hannum et al., 1996;
Wang and Shlomchik, 1999).
Depletion of CD4+ T cells
For CD4+ T cell depletion, GK1.5 was produced and purified as described
(Shlomchik et al., 1993). Mice were injected i.p. with GK1.5 or control rat
gamma globulin (Rockland). For most experiments, mice were injected with
2.0 mg of antibody twice per week. For inhibition of the T cell-dependent re-
sponse to NP-CGG, mice were treated with 4.0 mg/week of GK1.5 for one
week, then immunized with 100 mg NP-CGG emulsified in alum, as previously
described (Rossbacher and Shlomchik, 2003). Mice were then treated with
GK1.5 (4.0 mg/week) for an additional 10 days, at which time T cell depletion
and antibody production were determined.
Anti-Chromatin Hybridomas
The IgG2a and IgG2b anti-chromatin hybridomas, PL2-3 and PL2-8 (Losman
et al., 1993), were obtained from M. Monestier. For in vivo hybridoma growth,
mice were first injected with 0.25 ml of pristane (Sigma) on days 0 and 7. Hy-
bridoma cells were injected (107 cells) i.p. on day 10, and mice were sacrificed
on day 17 or 18. For cell-transfer experiments, ascites grown in BALB/c Rag-
deficient mice was used as a source of PL2-3 or PL2-8, with dosages deter-
mined by quantitating of IgG concentrations in the ascites by ELISA.
Antibody Reagents
Abs, prepared in our laboratory as described (Shlomchik et al., 1993), were:
4-44 biotin (anti-AM14 idiotype), 4-44 FITC, 4-44 Alexa Fluor 647, 4-44 Alexa
Fluor 488, 4-44 Alexa 568, GL1 (anti-CD86) FITC, 160A1 (anti-CD80) Alexa Fluor
488, and Pgp-1 (anti-CD44) Alexa Fluor 488. Anti-CD22.2 FITC, anti-CD22.2 PE,
and anti-CD138 PE were from BD PharMingen. BM8-Alexa647 (anti-F4/80) and
A3-1 biotin (anti-F4/80) were from Caltag. Streptavidin-Alexa 647 and strepta-
vidin-PE were from Molecular Probes. PNA-FITC was from Vector.
The anti-TCRd depleting antibody UC7-13D5 (Houlden, 1989) was obtained
from Zhinan Yin and Joseph Craft. Two hundred micrograms (Hiromatsu,
1992) was administered i.p. the day before the hybridoma cell injection and,
subsequently, every other day until the mice were sacrificed.
Protein Immunological Complexes
Immunological complexes were generated by combining of 125 mg of 23.3
(IgG2a anti-NP) and 31.25 mg of NP-CGG (per mouse) and incubation of the
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described (Rossbacher and Shlomchik, 2003) and injected i.p. into mice.
Flow Cytometry
Flow-cytometric analysis was performed as described (Shlomchik et al.,
1993). Data were collected on a FACSCalibur or an LSRII. Dead cells were ex-
cluded in all experiments with the use of either propidium iodide or ethidium
monoazide. After surface staining with 4-44-biotin and streptavidin-PE-Cy7,
intracellular staining with 4-44 was performed by fixation in 1% paraformalde-
hyde followed by permeabilization with Perm/Wash (BD Biosciences) and
staining with 4-44 conjugated with Alexa 647 overnight.
Histology and Immunofluorescence
Sections of spleen were prepared and stained as described (Hannum et al.,
2000). Nuclei were identified with 40,60-diamidino-2-phenylindole (Molecular
Probes). Images were captured on an Olympus BX-40 microscope with
a SPOT-RT Slider (Scanalytics) digital camera. 4-44-FITC or 4-44-biotin anti-
bodies, along with anti-FITC-alkaline phosphatase (Molecular Probes) and
streptavidin-HRP (Southern Biotechnology Associates), were used for immu-
nohistochemistry. Sections were developed with Fast Blue BB or 3-amino-9-
ethyl-carbazole (Sigma-Aldrich), as described previously (Hannum et al., 1996).
Laser Microdissection
Splenic sections were cut from OCT-embedded tissues and placed onto Leica
PEN-membrane 2.0 mm slides and stained for identification of extrafollicular
AM14 B cells. AM14 B cell clusters (10–30 cells) were dissected with the use
of a Leica LMD6000, and cells were digested for 1 hr at 55C in 10 ml of 0.8
mg/ml proteinase K, 50 mM Tris, pH 8, 50 mM KCl, 0.63 mM EDTA, 0.22%
Igepal, and 0.22% Tween 20.
Sequencing
Sequencing was performed as described (William et al., 2002), except with Pfu
Ultra rather than Pfu Turbo (Stratagene).
Cell Transfer
9 3 106 AM14 Balb/c B cells heterozygous or deficient for MyD88 were iso-
lated, labeled with carboxy-fluorescein succinimide ester (CFSE, Invitrogen)
according to manufacturer’s instructions, and transferred into BALB/c mice
i.v. on day 0. B cells were purified from spleens with the use of an Easy-Sep
kit (StemCell Technologies) and were typically > 95% pure. Ascites containing
the equivalent of 500 mg PL2-3 or PL2-8 was given i.p. on days 0, 2, 4, and 6.
Mice were sacrificed on day 8 and assessed as indicated.
SUPPLEMENTAL DATA
Supplemental Data include three figures and can be found with this article on-
line at http://www.immunity.com/cgi/content/full/29/2/249/DC1/.
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